0 NASDAQ Companies - October 19, 2020Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Dave & Buster’s Announces Proposed Private Offering of $500 Million of Senior Secured Notes Due 2025 by its Subsidiary Dave & Buster’s, Inc.Read More
0 NASDAQ Companies - October 19, 2020Dave & Buster’s Announces Proposed Private Offering of $500 Million of Senior Secured Notes Due 2025 by its Subsidiary Dave & Buster’s, Inc.Read More
0 NASDAQ Companies - October 19, 2020Dave & Buster’s Announces Proposed Private Offering of $500 Million of Senior Secured Notes Due 2025 by its Subsidiary Dave & Buster’s, Inc.Read More
0 NASDAQ Companies - October 19, 2020Dave & Buster’s Announces Proposed Private Offering of $500 Million of Senior Secured Notes Due 2025 by its Subsidiary Dave & Buster’s, Inc.Read More
0 NASDAQ Companies - October 19, 2020Dave & Buster’s Announces Proposed Private Offering of $500 Million of Senior Secured Notes Due 2025 by its Subsidiary Dave & Buster’s, Inc.Read More
0 NASDAQ Companies - October 19, 2020WMG Acquisition Corp. Announces Launch of $250 Million Additional Senior Secured Notes OfferingBay Street NewsRead More
